Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General Business Update

Oslo, Norway, 8 May 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic 'off the shelf' T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces its first quarter 2025 results today.Conference call and webcast scheduled for 8 May , 2025, at 09:00 (CET). Link to webcast here .First Quarter 2025 Business UpdateHighlightsOn 3 March 2025, Zelluna ASA announced the successful completion of a business combination between...

Oslo, 08/05/2025 (informazione.news - comunicati stampa - salute e benessere)

Oslo, Norway, 8 May 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic 'off the shelf' T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer,  announces its first quarter 2025 results today.

Conference call and webcast scheduled for 8 May , 2025, at 09:00 (CET). Link to webcast here .

First Quarter 2025 Business Update

Highlights

Financial update

The quarterly report and presentation will be published at 07:00 CET on 8 May, 2025, and will be publicly available on the Zelluna website. The Company will conduct a conference call and webcast at 09:00 CET the same day. Questions can be submitted throughout the event. The webcast will be archived for replay following the conference call. Link to webcast here .

For further information, please contact:

Namir Hassan, CEO, Zelluna ASA
Email: namir.hassan@zelluna.com
Phone: +44 7720 687608

Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com
Phone: +47 482 48632

About Zelluna ASA

Zelluna's mission is to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global scale. The Company aims to do this by combining the most powerful elements of the immune system through pioneering the development of “off the shelf” T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). The TCR-NK platform offers a unique mechanism of action with broad cancer detection capability to overcome the diversity of tumours and will be used “off the shelf” to overcome scaling limitations of current cell therapies. The lead program is a world's first MAGE-A4 targeting “off the shelf” TCR-NK for the treatment of various solid cancers; a pipeline of earlier products follows. The Company is led by a management team of biotech entrepreneurs with deep experience in discovery through clinical development of TCR and cell-based therapies including marketed products.

For more information, please visit  www.zelluna.com

This stock exchange announcement was published by Joachim Midttun, Financial Manager at Zelluna ASA, on 8 May, 2025 at 07:00 CET.

Attachments